EN
HI
Bafna Pharmaceuticals Chart
Bafna Pharmaceuticals Share Key Metrics
Volume
4042.00
Market Cap
327.62 CR
LTQ@LTP
102@145.41
ATP
145.02
Var Margin
25 %
Circuit Range
131.57-145.41
Delivery %
96.81 %
Value
5.86 L
ASM/GSM
No
Market Lot
1
Summary
Bafna Pharmaceuticals share price is ₹145.41 as of 2 Jun, 2026. The stock Bafna Pharmaceuticals intraday movement has stayed between ₹144.30 and ₹145.41, while on a 52-week basis,Bafna Pharmaceuticals price 52 week high is ₹202.06 & its 52 week low is ₹72.01.
In terms of trading activity, Bafna Pharmaceuticals has recorded a volume of 4042 shares, The Bafna Pharmaceuticals has a market cap of ₹23656335 CR. The stock’s Average Traded Price (ATP) stands at ₹145.02, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 102 @ ₹145.41.
Bafna Pharmaceuticals operates within a circuit range of ₹131.57 – ₹145.41, with a Value of ₹5.86 L. The Delivery Percentage for the day is 96.81%. Additionally, Bafna Pharmaceuticals currently falls under the No framework, and trades with a market lot size of 1.
Bafna Pharmaceuticals Fundamentals
View MoreP/E Ratio
0
P/B Ratio
0
Div. Yield
0
Sector P/E
55.51
Sector P/B
3.01
Sec. Div. Yield
0.55
Bafna Pharmaceuticals Resistance and Support
Pivot 136.99
Resistance
First Resistance
139.98
Second Resistance
141.48
Third Resistance
144.47
Support
First Support
135.49
Second Support
132.5
Third Support
131
Bafna Pharmaceuticals Corporate Actions
| Date | Agenda |
|---|---|
| 2026-05-29 | Audited Results |
| 2025-08-12 | Quarterly Results |
Bafna Pharmaceuticals News
Bafna Pharmaceuticals Ltd - 532989 - Board Meeting Outcome for Outcome Of The Board Meeting Held On May 29, 2026
Bafna Pharmaceuticals approved Q4 FY26 and full year FY26 audited financial results. Q4 total income increased 9.77% YoY to ₹44.00 crore, with net profit up 109.69% YoY to ₹2.75 crore. Auditors issued an unmodified opinion for the financial results.
May 29 2026 18:39:03
Bafna Pharmaceuticals Ltd - 532989 - Board Meeting Intimation for Meeting Scheduled On May 29, 2026
Bafna Pharma's Board of Directors is scheduled to meet on May 29, 2026. The key agenda is to consider and approve the audited financial results for the fourth quarter and full financial year ended March 31, 2026.
May 21 2026 17:58:44
Bafna Pharmaceuticals Management
| Name | Position |
|---|---|
| Shanmugam Hemalatha | Whole Time Director |
| Vinayak Dinesh Dendukuri | Whole Time Director - Quality |
Bafna Pharmaceuticals Similar Stocks
Bafna Pharmaceuticals FAQs
The Buying Price of Bafna Pharmaceuticals share is 145.41 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Bafna Pharmaceuticals stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Bafna Pharmaceuticals, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Bafna Pharmaceuticals shares is 0. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Bafna Pharmaceuticals shares is 0. Useful to assess the stock's value relative to its book value.
To assess Bafna Pharmaceuticals’s valuation compare Sector P/E, P/B which are 55.51 & 3.01 with sector averages, along with growth rates and financial metrics.
The Market Cap of Bafna Pharmaceuticals is 327.62 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Bafna Pharmaceuticals share price is 202.06 & 72.01. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Bafna Pharmaceuticals belongs to the Healthcare sector.
